FDA authorizes Ryoncil for steroid-refractory intense graft-versus-host after allo-HSCT
The allogeneic bone marrow-derived mesenchymal stromal cell (MSC) treatment Ryoncil (remestemcel-L-rknd) has actually been authorized for treatment for steroid-refractory intense graft-versus-host illness (SR-aGVHD) in pediatric clients aged 2 months or older, according to a news release from the U.S. Food and Drug Administration.
Ryoncil is the very first FDA-approved MSC treatment. MSCs are separated from the bone marrow of healthy adult human donors and are utilized to deal with SR-aGVHD in clients who go through ...